If you’ve been scrolling past headlines about Ozempic, Wegovy, or “GLP-1 drugs” without knowing what they actually are, you’re not alone. These medications have become household names practically overnight, but the science behind them is less widely understood. This guide breaks down what GLP-1 agonists do, which drugs fall into this class, how they help with both diabetes and weight loss, and what side effects to expect — all grounded in medical sources.

4 related posts

Quick snapshot

1Confirmed facts
2What’s unclear
3Timeline signal
  • FDA approvals for weight loss (Wegovy, Zepbound, Saxenda) occurred post-2020 (GoodRx)
4What’s next
  • Ongoing studies continue comparing individual drug efficacy (Mayo Clinic)

Primary Use: Type 2 Diabetes Management · Secondary Benefit: Weight Loss · Class Type: GLP-1 Receptor Agonists · Key Citation Count: 427 (NCBI StatPearls) · Common Examples: Ozempic and Others

Label Value
Drug Class GLP-1 Receptor Agonists
Main Conditions Type 2 Diabetes, Obesity
Mechanism Mimic GLP-1 hormone for glucose control
Top Source Cleveland Clinic, NCBI
Weight Loss Role Hunger control and blood sugar support

What drugs are GLP-1 agonists?

GLP-1 agonists are a class of injectable medications that mimic the glucagon-like peptide-1 hormone, which the gut naturally releases after eating. These drugs help manage blood sugar levels in people with type 2 diabetes by stimulating insulin release, slowing gastric emptying, and reducing appetite — a combination that also makes them effective for weight loss.

The most recognizable names in this class include semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss), tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss), liraglutide ( Victoza and Saxenda), dulaglutide (Trulicity), and exenatide (Byetta). According to the Mayo Clinic, tirzepatide and semaglutide are the most effective GLP-1 agonists for weight loss, while liraglutide and dulaglutide are classified as very effective.

Common GLP-1 agonist names

These medications come in both short-acting and long-acting formulations. Short-acting options like exenatide are typically injected twice daily, while long-acting versions such as semaglutide, liraglutide, and dulaglutide require weekly injections. The convenience factor matters: fewer injections generally correlate with better adherence in clinical practice.

The catch

Semaglutide side effects include abdominal pain, bloating, constipation, diarrhea, gas, and loss of appetite, according to BSW Health. Tirzepatide produces a similar profile: abdominal pain, constipation, diarrhea, indigestion, nausea, and vomiting.

GLP-1 drugs list

The FDA has approved several GLP-1 agonists specifically for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). For diabetes management, additional options include Ozempic (semaglutide), Mounjaro (tirzepatide), Victoza (liraglutide), Trulicity (dulaglutide), and Byetta (exenatide). These approvals reflect the dual benefit these medications offer in managing both conditions.

Is GLP-1 the same as Ozempic?

No — this is a common point of confusion. GLP-1 is a hormone your body produces naturally in the intestines. Ozempic, on the other hand, is a brand name for semaglutide, which is a lab-manufactured medication that mimics the GLP-1 hormone. Think of it like the difference between insulin the hormone and insulin the medication.

GLP-1 agonists work by binding to the same receptors in the pancreas and brain that natural GLP-1 activates, triggering insulin secretion and feelings of fullness. As documented by Endocrinology Advisor, these medications slow gastric emptying, leading to sustained feelings of fullness, reduced appetite, and decreased food intake.

The Cleveland Clinic explains that GLP-1 agonists are specifically used to treat type 2 diabetes mellitus and, in some formulations, obesity. Ozempic is one specific drug within this broader class — there is no single medication called “GLP-1” that patients can take.

Key distinction

Patients seeking weight loss specifically should ask their doctor about Wegovy or Zepbound, which are FDA-approved for that indication. Ozempic and Mounjaro are primarily approved for diabetes, though physicians may prescribe them off-label for weight management.

Who cannot take GLP-1?

Certain patients should avoid GLP-1 agonists or use them with caution. According to GoodRx, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take these medications. Additionally, patients with a history of pancreatitis may need alternative treatments after consulting with their healthcare provider.

Contraindications for GLP-1 agonists

Beyond thyroid concerns, GLP-1 agonists require caution in patients with severe gastrointestinal disease, including gastroparesis (partial paralysis of the stomach), since these drugs further slow gastric emptying. Patients with a history of bowel obstruction or severe Crohn’s disease should discuss alternatives with their physician.

Pregnancy and breastfeeding also contraindicate GLP-1 agonist use. Women of childbearing age should discontinue these medications well before planned conception. Kidney function matters too — the PMC adverse effects review notes that acute kidney injury can occur due to volume contraction from nausea, vomiting, and diarrhea, making patients with existing kidney impairment more vulnerable.

The hypoglycemia risk deserves specific attention: when combined with sulfonylureas or insulin, GLP-1 agonists can push blood sugar below the <70 mg/dL threshold. Per Cleveland Clinic, this risk increases substantially, requiring dose adjustment of those concurrent medications.

What is the biggest side effect of GLP-1?

Nausea is the most frequently reported side effect of GLP-1 agonists. Research published in PMC confirms that nausea is the most common gastrointestinal symptom, though it tends to be transient and improves as the body adjusts. The Cleveland Clinic lists loss of appetite, nausea, vomiting, and diarrhea as the primary adverse effects that patients experience.

Common adverse effects of GLP-1 receptor agonists

Gastrointestinal symptoms dominate the side effect profile. According to GoodRx, these effects — including nausea, vomiting, bloating, diarrhea, and constipation — are most pronounced when starting treatment or increasing doses. Gradual dose escalation, as noted by Endocrinology Advisor, can substantially reduce these symptoms.

Beyond GI issues, other reported side effects include dizziness, mild tachycardia, headaches, indigestion, injection site reactions, fatigue, hair loss, heartburn, and increased heart rate. Cleveland Clinic documents these additional reactions that, while less common, affect some patients throughout treatment.

The trade-off

Rapid weight loss from GLP-1s can lead to muscle loss and facial fat loss — colloquially termed “Ozempic face” by Harvard Health Publishing. This cosmetic side effect concerns patients who achieve dramatic results but notice accelerated aging in their facial appearance.

Rare but serious adverse effects

Though uncommon, serious complications warrant awareness. GoodRx identifies pancreatitis, gallbladder problems including gallstones, acute kidney damage, gastroparesis, and bowel obstruction as rare but documented risks. PMC research adds that these serious adverse events are uncommon but require prompt medical attention if symptoms develop.

Gallbladder issues appear more likely with higher doses and longer duration of use. The bone fracture picture is nuanced: PMC’s meta-analysis found that liraglutide is associated with a decreased bone fracture risk (MH-OR 0.38), while exenatide shows an increased risk (MH-OR 2.09). These competing effects suggest patients with osteoporosis concerns should discuss medication-specific risks with their doctor.

GLP-1 agonists for weight loss

The weight loss application of GLP-1 agonists represents a major shift in how healthcare providers approach obesity management. These medications reduce appetite and food cravings by activating satiety centers in the brain, counteracting the compensatory decrease of leptin (the fullness hormone) that typically occurs during weight loss, as explained by Endocrinology Advisor.

How to get started with GLP-1 medications for weight loss

Patients interested in GLP-1 agonists for weight loss typically need a prescription from a healthcare provider who will evaluate their BMI, medical history, and weight loss goals. Insurance coverage varies significantly — some plans cover these medications for diabetes but not for weight loss alone, creating a financial barrier for many patients.

The Mayo Clinic notes that tirzepatide and semaglutide lead in weight loss efficacy among the class, though the amount of weight loss depends on the specific medication and dose. Patients should expect gradual results rather than dramatic overnight transformations.

Why this matters

The cardiovascular benefits extend beyond weight loss. StatPearls – NCBI documents that GLP-1 agonists improve cardiovascular parameters including left ventricular ejection fraction and reduce cardiovascular event risks — a crucial consideration for patients with both obesity and heart disease risk factors.

Availability considerations

Supply shortages have affected GLP-1 agonist availability, particularly for semaglutide products. Patients may face delays in obtaining their prescriptions, and some pharmacies have implemented rationing policies. Those considering these medications should discuss backup options with their prescriber in case of supply disruptions.

Upsides

  • Effective for type 2 diabetes management and weight loss
  • Once-weekly injection options improve adherence
  • Cardiovascular benefits beyond glucose control
  • FDA-approved options available for both diabetes and obesity
  • Gradual dose titration reduces GI side effects

Downsides

  • Common GI side effects (nausea, vomiting, diarrhea)
  • Risk of hypoglycemia when combined with sulfonylureas or insulin
  • Rare but serious risks (pancreatitis, bowel obstruction)
  • Supply shortages affecting availability
  • Insurance coverage inconsistent for weight loss indication
  • Cosmetic effects like “Ozempic face” from rapid weight loss
Drug Approved For Weight Loss Efficacy Common Side Effects
Semaglutide (Ozempic/Wegovy) Diabetes, Weight Loss Most effective Abdominal pain, nausea, diarrhea, constipation
Tirzepatide (Mounjaro/Zepbound) Diabetes, Weight Loss Most effective Abdominal pain, nausea, vomiting, diarrhea
Liraglutide (Victoza/Saxenda) Diabetes, Weight Loss Very effective Nausea, headache, dizziness, constipation
Dulaglutide (Trulicity) Diabetes Very effective Nausea, diarrhea, vomiting, abdominal pain
Exenatide (Byetta) Diabetes Moderate Nausea, hypoglycemia, headache

Related reading: Luka Doncic Weight Loss · Luka Doncic Weight Loss Diet

Don't miss these

Frequently asked questions

What is the GLP-1 hormone?

GLP-1 (glucagon-like peptide-1) is a hormone produced in the intestines after eating. It stimulates insulin release, slows digestion, and promotes feelings of fullness. GLP-1 agonists are lab-manufactured medications that mimic this hormone’s effects.

How do GLP-1 agonists work?

These medications bind to GLP-1 receptors in the pancreas and brain. They stimulate insulin secretion in response to food, slow gastric emptying to extend feelings of fullness, and reduce appetite by activating satiety centers. According to Endocrinology Advisor, this combination of effects makes them effective for both blood sugar control and weight management.

Are GLP-1 agonists safe for weight loss?

Yes, when prescribed appropriately. FDA-approved options like Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) have undergone clinical trials demonstrating safety and efficacy for weight loss, per GoodRx. However, they require medical supervision and are not appropriate for everyone.

What are examples of GLP-1 agonist drugs?

Common examples include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta). The Mayo Clinic notes that tirzepatide and semaglutide are the most effective for weight loss.

What conditions do GLP-1 agonists treat?

These medications are primarily used to treat type 2 diabetes mellitus and obesity. Per StatPearls – NCBI, the FDA has approved them for both conditions, with specific formulations designated for each indication.

How to get GLP-1 medications?

You need a prescription from a healthcare provider. They’ll evaluate whether you’re a candidate based on your medical history, current conditions (type 2 diabetes, obesity, or both), BMI, and other factors. Insurance coverage varies, and patients should discuss costs and coverage options with their prescriber.

What are common GLP-1 side effects?

The Cleveland Clinic lists loss of appetite, nausea, vomiting, and diarrhea as the most common effects. Less frequent reactions include dizziness, headaches, indigestion, injection site reactions, fatigue, hair loss, and increased heart rate. Rare serious effects include pancreatitis and gallbladder problems.

“All GLP-1 agonists can help with weight loss. But the amount of weight loss depends on the type of medicine and the dose. In general, studies have found that tirzepatide and semaglutide are the most effective for weight loss.”

— Mayo Clinic Medical Experts

“The most frequently exhibited side effects from GLP-1 agonists include nausea, vomiting, and diarrhea that could lead to an acute kidney injury due to volume contraction.”

— StatPearls – NCBI Medical Researchers

For patients with type 2 diabetes who are also overweight, GLP-1 agonists offer a treatment that addresses both conditions simultaneously — a rare combination in medicine. The cardiovascular benefits documented by StatPearls – NCBI add further value for those with heart disease risk. However, the decision to use these medications requires weighing the proven benefits against the real side effect burden and the practical realities of cost and availability.